Vivostat A/S

Their core work

Vivostat A/S is a Danish medical device SME developing tissue regeneration and sealing products for surgical use. Their core technology is applied to reducing anastomotic leakage — a serious, potentially fatal complication that occurs when surgical joins in the bowel fail to heal properly after colorectal cancer resection. Their Obsidian product is a tissue sealant/regeneration system designed to be applied during minimally invasive (laparoscopic) bowel surgery to reinforce the anastomosis site. The company operates in a niche but high-value space at the intersection of regenerative medicine and colorectal surgery.

What they specialise in

How they've shifted over time

Vivostat's two projects represent a single focused technology journey rather than a shift in direction. Their Phase 1 (2019) project described the technology as a "tissue sealant method," while the Phase 2 (2021) project reframes it as a "tissue regeneration method" — suggesting the product matured from a passive sealant concept toward an active biological regeneration mechanism. This refinement in framing likely reflects clinical validation results and a sharper understanding of the product's mechanism of action rather than a pivot in focus.

Vivostat is advancing a single deep-tech product through clinical-stage development; future collaborations would most likely involve clinical trial sites, colorectal surgery centers, or hospital networks rather than basic research partners.

How they like to work

Vivostat has acted exclusively as project coordinator in both H2020 projects, consistent with an SME-Instrument model where the company drives its own product development agenda. With zero consortium partners recorded, both projects appear to have been company-led with no formal consortium structure — typical for SME Instrument grants, which are designed to fund single companies rather than research consortia. Collaborators (e.g., clinical partners or subcontractors) may exist in practice but are not reflected in the CORDIS partnership data.

Based on available H2020 data, Vivostat has no recorded consortium partners and no cross-country collaborations within these projects. This is characteristic of SME Instrument funding, which does not require consortium partners — their clinical and commercial network likely exists outside the formal EU project structure.

What sets them apart

Vivostat occupies a very specific niche: a product company targeting anastomotic leak — one of the most feared complications in colorectal surgery, carrying mortality rates of 5-15% and affecting approximately 10% of bowel resection patients. Unlike university research groups studying this problem, Vivostat is a commercial entity with a named product (Obsidian) progressing through funded clinical development. For consortium builders in surgical oncology or medical devices, they bring a product-stage asset and clinical development experience rather than basic science.

Highlights from their portfolio

• OBSIDIAN
  The Phase 2 project secured €2.14M — among the largest single-company SME Instrument Phase 2 awards — to develop a tissue regeneration product addressing anastomotic leakage, a major unsolved clinical problem in colorectal cancer surgery.
• Obsidian
  The Phase 1 feasibility project (€50K) validated the core concept and enabled the progression to Phase 2, demonstrating the company's ability to navigate the full EU SME Instrument pipeline.